Thus, their data demonstrated that rapamycin improves the immunoregulatory capacity of MSCs from SLE patients and indicated the involvement of the mTOR signalling pathway in the immune disorders of SLE patients [132]. The gene discussed is MTOR; the disease is systemic lupus erythematosus.